Join the Dupixent group to help and get support from people like you.
Dupixent News
FDA Approves Dupixent for Chronic Spontaneous Urticaria
WEDNESDAY, April 23, 2025 – The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is...
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
WEDNESDAY, April 23, 2025 – Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published online April 3 in JAMA Ophthalmology. Yung-Yu ...
Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...
Dupilumab Efficacious for Atopic Dermatitis in Young Children
WEDNESDAY, Dec. 11, 2024 – Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published in the December issue of Advances in Therapy. ...
American College of Chest Physicians, Oct. 6-9
The annual meeting of the American College of Chest Physicians was held this year from Oct. 6 to 9 in Boston, hosting participants from around the world, including specialists and heath care p...
CHEST: Dupilumab for COPD Tied to Improvement in Health-Related Quality of Life
MONDAY, Oct. 7, 2024 – Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a study presented...
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
TUESDAY, Oct. 1, 2024 – The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive...
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled...
Dupixent Approved in the US as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
Paris and Tarrytown, N.Y. September 13, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17...
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
MONDAY, Aug. 12, 2024 – For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients, according to a...
Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis
THURSDAY, June 27, 2024 – For children with eosinophilic esophagitis, dupilumab results in a significantly higher percentage of histologic remission, according to a study published in the June 27...
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
FRIDAY, June 14, 2024 – There is no evidence to suggest that administration of live vaccines to patients receiving dupilumab is unsafe, and vaccine efficacy is not affected by dupilumab, according...
Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...
Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the...
Dupixent (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis...
Further information
Related condition support groups
Eczema, Eosinophilic Esophagitis, Chronic Rhinosinusitis with Nasal Polyps, Prurigo Nodularis, Asthma, Asthma - Maintenance, Contact Dermatitis, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Urticaria, Hives